PMID- 37025413
OWN - NLM
STAT- MEDLINE
DCOM- 20230410
LR  - 20230411
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Diabetic endothelial microangiopathy and pulmonary dysfunction.
PG  - 1073878
LID - 10.3389/fendo.2023.1073878 [doi]
LID - 1073878
AB  - Type 2 diabetes mellitus (T2DM) is a widespread metabolic condition with a high 
      global morbidity and mortality rate that affects the whole body. Their primary 
      consequences are mostly caused by the macrovascular and microvascular bed 
      degradation brought on by metabolic, hemodynamic, and inflammatory variables. 
      However, research in recent years has expanded the target organ in T2DM to 
      include the lung. Inflammatory lung diseases also impose a severe financial 
      burden on global healthcare. T2DM has long been recognized as a significant 
      comorbidity that influences the course of various respiratory disorders and their 
      disease progress. The pathogenesis of the glycemic metabolic problem and 
      endothelial microangiopathy of the respiratory disorders have garnered more 
      attention lately, indicating that the two ailments have a shared history. This 
      review aims to outline the connection between T2DM related endothelial cell 
      dysfunction and concomitant respiratory diseases, including Coronavirus disease 
      2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD) and 
      idiopathic pulmonary fibrosis (IPF).
CI  - Copyright (c) 2023 Zhang, Jiang, Xie, Mo, Zhang and Liu.
FAU - Zhang, Lanlan
AU  - Zhang L
AD  - Department of Respiratory and Critical Care Medicine, Division of Pulmonary 
      Diseases, State Key Laboratory of Biotherapy, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Jiang, Faming
AU  - Jiang F
AD  - Department of Respiratory and Critical Care Medicine, Division of Pulmonary 
      Diseases, State Key Laboratory of Biotherapy, West China Hospital of Sichuan 
      University, Chengdu, China.
FAU - Xie, Yingying
AU  - Xie Y
AD  - Department of Nephrology, Seventh Affiliated Hospital, Sun Yat-sen University, 
      Shenzhen, China.
FAU - Mo, Yan
AU  - Mo Y
AD  - Department of Neurology Medicine, The Aviation Industry Corporation of China 
      (AVIC) 363 Hospital, Chengdu, China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Gastroenterology, West China Hospital of Sichuan University, 
      Chengdu, China.
FAU - Liu, Chuntao
AU  - Liu C
AD  - Department of Respiratory and Critical Care Medicine, Division of Pulmonary 
      Diseases, State Key Laboratory of Biotherapy, West China Hospital of Sichuan 
      University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230321
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *COVID-19/complications
MH  - *Pulmonary Disease, Chronic Obstructive
MH  - Lung/pathology
MH  - Comorbidity
MH  - *Idiopathic Pulmonary Fibrosis/pathology
MH  - *Diabetic Angiopathies
MH  - *Vascular Diseases
PMC - PMC10071002
OTO - NOTNLM
OT  - COPD
OT  - COVID-19
OT  - asthma
OT  - endothelial cells
OT  - type-2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/08 06:00
MHDA- 2023/04/10 06:42
PMCR- 2023/03/21
CRDT- 2023/04/07 02:29
PHST- 2022/10/19 00:00 [received]
PHST- 2023/02/17 00:00 [accepted]
PHST- 2023/04/10 06:42 [medline]
PHST- 2023/04/07 02:29 [entrez]
PHST- 2023/04/08 06:00 [pubmed]
PHST- 2023/03/21 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1073878 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Mar 21;14:1073878. doi: 
      10.3389/fendo.2023.1073878. eCollection 2023.